LMTK3の高発現がERα陽性乳癌では予後不良因子となる<要約> by Tomoko Asano
  
Nagoya City University Academic Repository 
 
 
 
学 位 の 種 類 
 
 
  博士 (医学) 
 
報 告 番 号 
 
  甲第１４６７号 
 
学 位 記 番 号   第１０５３号 
 
氏    名 
 
 
  浅野 倫子 
 
 
授 与 年 月 日 
 
 
  平成 27 年 3 月 25 日 
 
 
 
 
 
学位論文の題名 
 
 
 
 
 
High expression of LMTK3 is an independent factor indicating a 
poor prognosis in estrogen receptor α-positive breast cancer 
patients 
(LMTK3 の高発現が ERα陽性乳癌では予後不良因子となる) 
 
Japanese Journal of Clinical Oncology, 44(10): 889-897, 2014 
 
 
 
 
論文審査担当者 
 
 
  主査： 高橋 智 
  副査： 稲垣 宏, 竹山 廣光 
 
 
Objective: Estrogen receptor α (ERα) is a member of the nuclear receptor family. Over 70% of 
breast cancers are ERα-positive, and endocrine therapy targeting estrogen action decreases mortality 
from breast cancer. Recently, a novel protein kinase that regulates ERα activity, lemur tyrosine 
kinase-3 (LMTK3) has been identified. In this study, we investigated whether LMTK3 mRNA 
expression and its polymorphisms are associated with prognosis in breast cancer patients during 
long-term follow-up. 
Methods: First, we investigated the relationship between mRNA expression of LMTK3 and patient 
outcome in 219 breast cancers. The effects of several variables on survival were tested by Cox 
proportional hazards regression analysis. Next, we performed LMTK3 genotyping in 471 breast 
cancers to clarify the prognostic role of these polymorphisms. 
Results: Our data showed that LMTK3 expression level was not associated with prognosis in all 
patients. We then analyzed the impact of LMTK3 mRNA expression on the prognosis of breast 
cancer according to ERα status. Both disease-free survival and overall survival were significantly 
shorter in ERα-positive patients with high LMTK3 expression receiving adjuvant endocrine therapy 
than in those patients with low LMTK3 expression. Multivariate Cox regression analysis revealed 
that high LMTK3 expression was an independent poor prognostic factor in ERα-positive breast 
cancer patients. We did not find any correlation between LMTK3 genotypes and prognosis of breast 
cancer patients in our series. 
Conclusions: Our results show that high expression of LMTK3 is an independent prognostic factor 
in ERα-positive breast cancer patients receiving adjuvant endocrine therapy. 
 
